|
| 37865290 | A New Set of in Silico Tools to Support the Interpretation of ATM Missense Variants Using Graphical Analysis. | J Mol Diagn | 2024 |
| 36948887 | p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. | J Pathol Clin Res | 2023 |
| 35084436 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. | JAMA Oncol | 2022 |
| 35737787 | Small-molecule activation of OGG1 increases oxidative DNA damage repair by gaining a new function. | Science | 2022 |
| 35595798 | Apparent regional differences in the spectrum of BARD1 pathogenic variants in Spanish population and importance of copy number variants. | Sci Rep | 2022 |
| 35619904 | OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells. | Front Oncol | 2022 |
| 35933885 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model. | Eur J Cancer | 2022 |
| 36230663 | A Large Case-Control Study Performed in Spanish Population Suggests That <i>RECQL5</i> Is the Only RECQ Helicase Involved in Breast Cancer Susceptibility. | Cancers (Basel) | 2022 |
| 33471991 | Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. | N Engl J Med | 2021 |
| 33568707 | Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects. | Sci Rep | 2021 |
| 33990587 | Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. | Nat Commun | 2021 |
| 33280026 | A Collaborative Effort to Define Classification Criteria for ATM Variants in Hereditary Cancer Patients. | Clin Chem | 2021 |
| 32554541 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). | Clin Cancer Res | 2020 |
| 31723001 | Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. | Cancer Res | 2020 |
| 31797087 | Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH). | Virchows Arch | 2020 |
| 32107557 | Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. | J Natl Cancer Inst | 2020 |
| 31792088 | Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. | Cancer Epidemiol Biomarkers Prev | 2020 |
| 32555365 | Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. | Br J Cancer | 2020 |
| 30683880 | Shared heritability and functional enrichment across six solid cancers. | Nat Commun | 2019 |
| 31548585 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers. | Nat Commun | 2019 |
| 30817846 | RECQL5: Another DNA helicase potentially involved in hereditary breast cancer susceptibility. | Hum Mutat | 2019 |
| 30747491 | A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers. | Mol Oncol | 2019 |
| 28837162 | Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. | Genet Med | 2018 |
| 30054336 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. | Cancer Res | 2018 |
| 31360853 | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. | JNCI Cancer Spectr | 2018 |
| 30873510 | The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With <i>BRCA1</i> or <i>BRCA2</i> Mutations. | JNCI Cancer Spectr | 2018 |
| 29446198 | Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. | Hum Mutat | 2018 |
| 27913932 | Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene. | Breast Cancer Res Treat | 2017 |
| 28448241 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. | J Clin Oncol | 2017 |
| 28346442 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. | Nat Genet | 2017 |
| 28283652 | <i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. | Cancer Res | 2017 |
| 29383107 | Genetic variation in the <i>NEIL2</i> DNA glycosylase gene is associated with oxidative DNA damage in <i>BRCA2</i> mutation carriers. | Oncotarget | 2017 |
| 29058716 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. | Nat Genet | 2017 |
| 29049607 | Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. | JAMA Oncol | 2017 |
| 28829762 | Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes. | Br J Cancer | 2017 |
| 28632866 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. | JAMA | 2017 |
| 27796716 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. | Breast Cancer Res Treat | 2017 |
| 25940428 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. | Gynecol Oncol | 2016 |
| 27601076 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. | Nat Commun | 2016 |
| 27742776 | Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect. | Hum Mol Genet | 2016 |
| 27117709 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. | Nat Commun | 2016 |
| 27459855 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. | Breast Cancer Res | 2016 |
| 26857456 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. | Breast Cancer Res | 2016 |
| 27015555 | Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers. | Oncotarget | 2016 |
| 26928228 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. | Nat Genet | 2016 |
| 24917463 | MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors. | Int J Cancer | 2015 |
| 26586665 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. | J Natl Cancer Inst | 2015 |
| 26130695 | FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. | Hum Mol Genet | 2015 |
| 26071757 | DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers. | Breast Cancer Res Treat | 2015 |
| 25830658 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. | PLoS One | 2015 |